A Phase 2, Historically Controlled Study Testing the Efficacy of TTFields (Optune®) with Adjuvant Temozolomide in High-risk WHO Grade II and III Astrocytomas (FORWARD)

December 20, 2019
https://clinicaltrials.gov/ct2/show/NCT03906448
Cancer - Brain
Principal Investigator: James M Snyder, DO
Astrocytomas, Temozolomide, TTFields, Optune
Open